Last reviewed · How we verify
Clopidogrel with aspirin
Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots.
Clopidogrel and aspirin together inhibit platelet aggregation through complementary pathways to prevent blood clots. Used for Acute coronary syndrome, Secondary prevention after myocardial infarction, Stroke prevention in patients with recent ischemic stroke or transient ischemic attack.
At a glance
| Generic name | Clopidogrel with aspirin |
|---|---|
| Also known as | Plavix |
| Sponsor | University of Florida |
| Drug class | Dual antiplatelet agent |
| Target | P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Clopidogrel is a P2Y12 receptor antagonist that blocks ADP-induced platelet activation, while aspirin irreversibly inhibits cyclooxygenase to prevent thromboxane A2 production. Together, they provide dual antiplatelet therapy with synergistic effects to reduce thrombotic events.
Approved indications
- Acute coronary syndrome
- Secondary prevention after myocardial infarction
- Stroke prevention in patients with recent ischemic stroke or transient ischemic attack
- Coronary stent thrombosis prevention
Common side effects
- Bleeding
- Dyspepsia
- Rash
- Diarrhea
- Thrombotic thrombocytopenic purpura (TTP)
Key clinical trials
- The Effect and Safety of Combined Anti-platelet Treatment in Acute Ischemic Stroke Due to Large Artery Atherosclerosis (PHASE4)
- Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure (PHASE4)
- Randomized Clinical Trial of Endovascular Recanalization for Symptomatic Non-Acute Intracranial Artery Occlusion（REPAIR） (NA)
- Clopidogrel vs. Aspirin for Cardiovascular Risk Reduction in Patients With S. Aureus Bacteremia (PHASE4)
- Precision Reperfusion Therapy for Disabling Minor Stroke With Large Vessel Occlusion Beyond Time Window (PHASE3)
- SIMPLAAFY Clinical Trial (NA)
- STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant (PHASE4)
- Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Clopidogrel with aspirin CI brief — competitive landscape report
- Clopidogrel with aspirin updates RSS · CI watch RSS
- University of Florida portfolio CI